While further research is needed to delineate dosage, specificity, and long-term effects, the off-target inhibition of NLRP3 by conventional and natural agents underscores the translational potential of repurposed or adjunctive therapies in treating inflammation-driven complications in T2DM and CVD. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.